Biomed Middle East

Jasco receives grant under PPACA Act to develop therapeutics for cancer treatment

Jasco Pharmaceuticals, LLC was awarded a grant under the US Government’s Patient Protection and Affordable Care Act (PPACA) of 2010. The grant was related to Jasco Pharma’s novel small molecule Pim inhibitor program intended to develop therapeutics for the treatment of cancer.

“We are excited to receive the grant in recognition that our innovative Pim inhibitor program shows promise to bring forward a novel oncology therapeutic”

“We are excited to receive the grant in recognition that our innovative Pim inhibitor program shows promise to bring forward a novel oncology therapeutic,” said Carmen Baldino, president of Jasco Pharmaceuticals, “This funding will assist in accelerating the development of our program.”

Source: Jasco Pharmaceuticals

Exit mobile version